Crossmark

The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US

Crossref DOI link: https://doi.org/10.1007/s40259-022-00557-3

Published Online: 2022-09-27

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ghanem, Buthainah https://orcid.org/0000-0003-1682-4867
Shi, Lu
License Information

Text and Data Mining valid from 2022-09-27

Version of Record valid from 2022-09-27
More Information

Article History

Accepted: 13 September 2022

First Online: 27 September 2022

Declarations

:

: No external funding was used in the preparation of this article.

: Buthainah Ghanem and Lu Shi declare that they have no conflicts of interest that might be relevant to the contents of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: All data generated or analyzed during this study are included in this published article.

: Not applicable.

Document is current

Any future updates will be listed below